Kaikai Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kaikai Yu has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- He Xiao
State Key Laboratory of National Security Specially Needed Medicines, Beijing 100850, China
1 shared publication Hui Shu
Academy of Military Medical Sciences
1 shared publication- Shuang Xing
Academy of Military Medical Sciences, Beijing 100850, China
1 shared publication Wanlu Zhu
State Key Laboratory of National Security Specially Needed Medicines
1 shared publicationXing Shen
Academy of Military Medical Sciences
1 shared publication- Zuyin Yu
Academy of Military Medical Sciences
1 shared publication
Latest Publications
- Open Access
- 15 June 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (25) , 37090-37101
Novel Thrombopoietin-Mimetic Peptide 2B9F: A Promising Therapeutic Candidate for Hematopoietic Acute Radiation Syndrome
Therapeutic interventions for hematopoietic acute radiation syndrome (H-ARS) remain limited in both variety and efficacy, falling short of achieving durable recovery of the hematopoietic system. Here, we develop 2B9F, a novel thrombopoietin-mimetic peptide engineered for enhanced stability and designed with the intention of achieving low immunogenicity. A single subcutaneous dose of 2B9F administered postexposure achieved complete survival in a lethal murine irradiation model, surpassing the efficacy of the clinically approved agent romiplostim. Treatment with 2B9F accelerated the recovery of peripheral blood counts and bone marrow nucleated cells, expanded functional hematopoietic stem cells (HSCs), and enhanced both in vitro clonogenic potential and in vivo competitive repopulation capacity. Mechanistic studies revealed that 2B9F promoted HSC quiescence and survival through transcriptional modulation of apoptosis and cell-cycle regulators. Importantly, a single low dose of 2B9F also conferred durable protection, mitigating delayed bone marrow suppression for up to six months postirradiation. These findings position 2B9F as a promising single-dose, low-immunogenicity therapeutic candidate for H-ARS, indicating strong potential for clinical translation in nuclear emergencies.
- 15 June 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (25) , 37090-37101
Open AccessNovel Thrombopoietin-Mimetic Peptide 2B9F: A Promising Therapeutic Candidate for Hematopoietic Acute Radiation Syndrome
Therapeutic interventions for hematopoietic acute radiation syndrome (H-ARS) remain limited in both variety and efficacy, falling short of achieving durable recovery of the hematopoietic system. Here, we develop 2B9F, a novel thrombopoietin-mimetic peptide engineered for enhanced stability and designed with the intention of achieving low immunogenicity. A single subcutaneous dose of 2B9F administered postexposure achieved complete survival in a lethal murine irradiation model, surpassing the efficacy of the clinically approved agent romiplostim. Treatment with 2B9F accelerated the recovery of peripheral blood counts and bone marrow nucleated cells, expanded functional hematopoietic stem cells (HSCs), and enhanced both in vitro clonogenic potential and in vivo competitive repopulation capacity. Mechanistic studies revealed that 2B9F promoted HSC quiescence and survival through transcriptional modulation of apoptosis and cell-cycle regulators. Importantly, a single low dose of 2B9F also conferred durable protection, mitigating delayed bone marrow suppression for up to six months postirradiation. These findings position 2B9F as a promising single-dose, low-immunogenicity therapeutic candidate for H-ARS, indicating strong potential for clinical translation in nuclear emergencies.